- Home
- Products
DANYELZA (naxitamab-gqgk)
DANYELZA (naxitamab-gqgk)
- Medicine Name: Danyelza®
- Generic Name: Naxitamab-gqgk
- Dosage Form & Strength: Injection – 40 mg/10 mL (4 mg/mL), single-dose vial
- Manufactured By: Y-mAbs Therapeutics, Inc.
- FDA Approval: November 25, 2020
Danyelza® is used in combination with GM-CSF (granulocyte-macrophage colony-stimulating factor) to treat:
- Pediatric patients aged 1 year and older
- Adults with relapsed or refractory high-risk neuroblastoma
- Specifically for disease in the bone or bone marrow who show partial, minor, or stable response to prior therapy
Dosage & Administration
- Dose: 3 mg/kg/day (max 150 mg/day)
- Schedule: IV infusion on Days 1, 3, and 5 of each 28-day cycle
- Cycle Frequency: Every 4 weeks (initially), then every 8 weeks
- Along with: Subcutaneous GM-CSF before and during each cycle
- Discontinue if: Disease progresses or side effects become unacceptable
🚫 Do not use in patients with a history of severe hypersensitivity to naxitamab
⚠️ Risk of neurotoxicity, including transverse myelitis and RPLS (reversible posterior leukoencephalopathy syndrome)
🩺 Monitor blood pressure daily on Days 1–8 of each cycle
⚠️ Avoid during pregnancy – may cause fetal harm
📋 Use under specialist supervision only; cardiac and neurological monitoring is recommended
To import Danyelza®, the following documents are required:
- ✅ Valid prescription from a certified oncologist
- ✅ Patient’s diagnostic reports
- ✅ Government-issued ID proof of the patient
The order will be processed only after receiving all documents and, if required, the import permit.
Availability
Danyelza® can be arranged by Indian Pharma Network (IPN) across cities including:
Delhi, Mumbai, Bangalore, Kolkata, Chennai, Hyderabad, Ahmedabad, Pune, Lucknow, Jaipur, Ludhiana, Noida, Gurgaon, Chandigarh, Jammu, Srinagar, and others.
Global delivery also available to countries like Nepal, Bangladesh, Sri Lanka, Maldives, Bhutan, Afghanistan, and Pakistan.
- 🌍 Sourced globally from certified suppliers (USA, Europe, Canada, Australia)
- ✅ Verified by licensed pharmacists
- 📦 Delivered directly to patient’s address in secure, temperature-controlled packaging
Q: What is Danyelza® used for?
A: Danyelza is used to treat high-risk neuroblastoma in the bone or bone marrow for patients who have not fully responded to previous therapies.
Q: How is it administered?
A: It is given via intravenous infusion over several treatment days in a 4-week cycle along with GM-CSF injections.
Q: What are the most common side effects?
A: Pain, infusion-related reactions, vomiting, fever, hypertension, rash, diarrhea, decreased appetite, and irritability.
Q: How is it stored?
A: Store refrigerated at 2°C to 8°C (36°F to 46°F). Keep in the original carton to protect from light.
Q: Can I buy Danyelza online safely in India?
A: Yes, through WHO-GDP and ISO-certified distributors like Indian Pharma Network.
Q: What is the price of Danyelza in India?
A: Contact +91-9310090915 or email info@globalraremeds.com to get a quote.
Contact Patient Support
If you have questions about your order, need assistance with documentation, or require support with medicine availability, our GlobalRareMeds Patient Support Team is here to help. We aim to respond within 24 hours, Monday to Friday, between 9:00 AM and 10:00 AM IST.
info@globalraremeds.com
Phone
+91 99675 15602
+91 99675 15602
Disclaimer
All trademarks, brands, and product names featured on this website are the property of their respective owners. GlobalRareMeds does not claim ownership or affiliation unless explicitly stated. Our role is to provide reliable and transparent access to difficult-to-source medicines through named-patient import services, based on valid prescriptions and legal requirements.
The product-related content on this website is shared to the best of our knowledge, compiled from publicly available sources and regulatory documents. However, GlobalRareMeds does not guarantee the accuracy, completeness, or timeliness of this information. We strongly recommend that all medical decisions, including usage and dosage, be made only in consultation with the prescribing doctor. GlobalRareMeds assumes no responsibility for consequences arising from reliance on this information without appropriate medical guidance
